预约演示
'Lots of ways for donanemab to win' in Alzheimer's, Lilly says. Now, it just needs the data
2023-04-27
临床3期临床2期加速审批
The Indianapolis Big Pharma is awaiting a crucial readout from the phase 3 TRAILBLAZER-ALZ 2 study for monoclonal antibody donanemab—a make or break result that investors are impatiently waiting for.
Analysts are desperately trying to read the tea leaves comparing Eli Lilly’s Alzheimer’s disease med and Eisai/Biogen’s Leqdonanemabre the mug is cool, but executives say there are “lots of ways for donanemab to win.”
Lilly executives remain bullish on donanemab’s market potential eEli LillytheAlzheimer’s diseasevantage lEisai Biogenby Biogen and Eisai.donanemab
Lilly will be a very important and donanemabl drug. I know it's interesting for investors to sort of speculate on competBiogenbetweEisaio different pharma companies. That’s not exactly how I think about it,” Chief Scientific and Medical Officer Daniel Skovronsky, M.D., Ph.D., said during Lilly’s first-quarter earnings call Thursday.
First, Lilly needs to see the data, which are due this half. The Indianapolis Big Pharma is awaiting a crucial readout from the phase 3 TRAILBLAZER-ALZ 2 study for the monoclonal antibody—a make or break result that investors are impatiently watching out for. Lilly was beaten to the markeLillyEisai and Biogen when Leqembi received accelerated approval in January, later receiving a no for the same early-market access request for donanemab. It’s likely that Eisai will get the full approval before Lilly, which has to wait for the phase 3 TRAILBLAZER data before submitting.
“The challenge is not really about competition. It's about how do we help the medical system better identify patients, diagnose them and move them into treatment regimens?” he said. Getting reimbursement from the Centers for Medicare & Medicaid Services is also needed to ensure access. The agency has kept in place a hold on coverage for only patients apart from those participating in clinical trials for Alzheimer’s monoclonal antibodies that are approved under the accelerated pathway.
But donanemab and Leqembi have key differences, Skovronsky noted. Lilly’s offering targets amyloid plaques and can have a fixed duration dosing schedule, meaning patients can in some instances take it and stop. Leqembi, meanwhile, is to be taken for longer.Alzheimer’s monoclonal antibodies
“Letdonanemabw theLeqembiurn out, but I expect that many patients Lillybe able to stop dosing even as soon as 12 months,” Skovronsky said. “That's a big difference than being prescribed a drug that you might havLeqembike the rest of your life. And I think that could be exciting and important for patients.”
“So [there’s] lots of ways for donanemab to win. I think the most important thing though, is showing consistent strong efficacy like we did in phase 2, and then getting this drug approved and bringing it to patients,” he concluded.
Anne White, president of Lilly donanemabnce, said she remains confident in the mid- to long-term markert opportunity for the therapy but reminded investors that “it will take time to build this market.”
“I don't think we really Lilly Neuroscience class of drugs we need to fight over market share,” White said. “It's an opportunity to build a new class on behalf of people with the disease, driving awareness, driving diagnosis and then getting access. So that's important to us in the near term.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。